Minapharm Pharmaceuticals S.A.E. specializes in developing, manufacturing and marketing prescription pharmaceutical products. The products are for the treatment of gastroenterological, ophthalmologic, cardiovascular, genetic, dermatological, orthopedic diseases, etc.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-07-12	EGP 698.08	-0.27%	2,019
26-07-09	EGP 700.00	+0.23%	3,799
26-07-08	EGP 698.41	+2.32%	15,399
26-07-07	EGP 682.55	-2.49%	1,168
26-07-06	EGP 700.00	+5.80%	6,221

End-of-day quote Egyptian Exchange

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Egyptian Exchange Other stock markets 2026-07-12			5-day change	1st Jan Change
698.08 ^EGP	-0.27%		+6.02%	+99.91%

06-10	MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-05	Minapharm pharmaceuticals FY standalone net profit EGP 57.5 million	RE

Market Cap	8.22B 165M 144M 133M 123M 234M 15.73B 238M 1.59B 624M 7.71B 619M 606M 26.69B	P/E 2024	14x	P/E 2025	584x
Enterprise Value	9.33B 187M 164M 151M 140M 265M 17.85B 270M 1.81B 708M 8.75B 703M 688M 30.29B	EV / Sales 2024	0.78x	EV / Sales 2025	0.81x
Free-Float	14.74%	Yield 2024	1.54%	Yield 2025	-

06-10	MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-05	Minapharm pharmaceuticals FY standalone net profit EGP 57.5 million	RE
11-30	Minapharm Pharmaceuticals Q3 consol profit egp 16.8 million	RE
11-29	MINAPHARM Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-09-14	MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-09-14	Minapharm Pharmaceuticals Q2 consol profit EGP 40 million	RE
25-07-27	MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-07-27	Minapharm Pharmaceuticals Q1 consol net loss EGP 2 million	RE
25-06-12	MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-06-12	Minapharm Pharmaceuticals FY Colsol Net Profit EGP 161.1 Million	RE
25-05-26	Minapharm Pharmaceuticals FY Standalone Profit EGP 162.8 Million	RE
24-12-03	MINAPHARM Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-09-01	MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI

25-07-07	EBRD, Admaius Capital plan to acquire 15%-20% of Egyptian Minapharm Pharmaceuticals	AQ
25-03-26	African Development Bank Approves Eur 15 Million Loan to Boost Biosimilars' Development and Production in Egypt	AQ
23-10-05	SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries	AQ
23-10-04	SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries This landmark MOU marks a significant step towards ensuring national health security and achieving biomanufacturing autonomy in Saudi Arabia	AQ
23-03-06	Participants Dosed of Adessia® in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa	AQ

MINAPHARM Pharmaceuticals Stock

Stocks

MIPH

EGS380G1C011

Pharmaceuticals

Valuation: MINAPHARM Pharmaceuticals

Chart: MINAPHARM Pharmaceuticals

Latest news : MINAPHARM Pharmaceuticals

Press Releases: MINAPHARM Pharmaceuticals

Quotes and Performance

Course Extremes

Managers and Directors: MINAPHARM Pharmaceuticals

Generic Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	-0.27%
1 week	+6.02%
Current month	+6.36%
1 month	+6.74%
3 months	+21.58%
6 months	+95.16%
Current year	+99.91%

1 week	656.11	708
1 month	630.13	710
Current year	320.23	772
1 year	214.7	772
3 years	145	772
5 years	96	772
10 years	45	772

Manager	Title	Age	Since
Shaheer Wafeeq Sa'ad Al-Bardissy CEO	Chief Executive Officer	-	-
Wafik El-Bardissy CEO	Chief Executive Officer	-	2010-10-18
Rafiq Raymond DFI	Director of Finance/CFO	-	-

Director	Title	Age	Since
Amr Mohamed Sobhi Hamza El-Shabrawishy BRD	Director/Board Member	-	-
Wafik El-Bardissy CHM	Chairman	-	2010-10-17
Anwar Nasr Mekhaeel BRD	Director/Board Member	-	2010-10-17

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MINAPHARM PHARMACEUTICALS	-0.27%	+6.02%	+199.79%	+217.32%	166M
SUN PHARMACEUTICAL INDUSTRIES LTD.	-0.17%	+1.61%	+15.76%	+80.51%	48.69B
OTSUKA HOLDINGS CO., LTD.	+1.04%	-1.02%	+67.19%	+116.18%	36.38B
CIPLA LIMITED	-0.13%	-1.29%	-3.07%	+40.05%	12.19B
ZYDUS LIFESCIENCES LIMITED	-0.71%	+0.89%	+17.48%	+96.77%	12.04B
KRKA, D. D.	-0.76%	+0.38%	+31.49%	+124.03%	9.04B
GEDEON RICHTER	+0.75%	-0.82%	+18.53%	+42.99%	7.09B
ONO PHARMACEUTICAL CO., LTD.	-0.86%	+0.37%	+50.57%	-3.02%	7.06B
GLENMARK PHARMACEUTICALS LIMITED	+0.69%	+3.25%	+4.67%	+240.43%	6.75B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	+5.45%	-7.36%	-17.51%	+14.39%	6.1B
Average	+0.50%	-0.41%	+38.49%	+96.96%	14.55B
Weighted average by Cap.	+0.34%	+0.09%	+28.28%	+89.01%

	2024	2025
Net sales	5.66B 114M 99.52M 91.93M 84.79M 161M 10.84B 164M 1.1B 430M 5.31B 427M 417M 18.38B	6.44B 129M 113M 104M 96.37M 183M 12.31B 186M 1.25B 488M 6.03B 485M 474M 20.89B
Net income	157M 3.15M 2.76M 2.55M 2.35M 4.46M 300M 4.54M 30.42M 11.91M 147M 11.83M 11.57M 510M	40.22M 807K 707K 653K 602K 1.14M 76.92M 1.16M 7.79M 3.05M 37.7M 3.03M 2.96M 131M
Net Debt	2.6B 52.11M 45.65M 42.16M 38.89M 73.8M 4.97B 75.06M 503M 197M 2.44B 196M 191M 8.43B	1.11B 22.26M 19.5M 18.01M 16.62M 31.53M 2.12B 32.07M 215M 84.21M 1.04B 83.59M 81.77M 3.6B